Avalo Therapeutics

Company snapshot

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com. Our highly targeted therapeutics have strong scientific and clinical rationale that enable accelerated clinical development and increased pro

• 17 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 17 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Avalo Therapeutics. Not investment advice.

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  MoonLake Immunotherapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for Avalo Therapeutics.

1. Jun 5, 2026 Clinical update

   Placebo to AVTX-009, AVTX-009 — Phase 2

2. Jun 5, 2026 Clinical update

   AVTX-009 Regimen 1 — Phase 2

3. May 23, 2026 Clinical update

   NFC-1 — Phase 3

4. May 23, 2026 Clinical update

   AEVI-001 — Phase 2

5. May 23, 2026 Clinical update

   AVTX-002 — Phase 2

View all clinical trial activity →

• What is Avalo Therapeutics?

  Avalo Therapeutics is a pharma organization headquartered in Chesterbrook, USA. It trades on NYSE under ticker AVTX. Primary therapeutic focus areas include Attention Deficit Disorder With Hyperactivity, Hidradenitis suppurativa (HS), Attention Deficit Hyperactivity Disorder, Mul

• Is Avalo Therapeutics publicly traded?

  Yes. Avalo Therapeutics is listed with ticker AVTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Avalo Therapeutics develop or market?

  We link 2 drug profile(s) where Avalo Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/avalo-therapeutics#company-drugs.

• What are the latest developments for Avalo Therapeutics?

  In the last 12 months our linked public records show 17 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Avalo Therapeutics focus on?

  Avalo Therapeutics focuses on Attention Deficit Disorder With Hyperactivity, Hidradenitis suppurativa (HS), Attention Deficit Hyperactivity Disorder based on our analysis of their pipeline programs and drug development activities.